ESC 365 - Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV

ESC Premium Access

Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV

Session: Cardiovascular Disease in Special Populations ePosters

Topic: Renal Failure and Cardiovascular Disease

Speaker: Professor D. Cherney (Toronto, CA)

Event: ESC Congress 2021 - The Digital Experience

Congress Session

About the speaker

Professor David Cherney

University of Toronto, Toronto (Canada)

0 follower

187 more presentations in this session

The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure

Speaker: Professor J. McMurray (Glasgow, GB)

CHA2DS2-VASc score as independent outcome predictor in patients with acute ischemic stroke with and without atrial fibrillation

Speaker: Doctor C. Su (Taichung, TW)

Type and severity of migraine determines long-term risk of atrial fibrillation in women: a nationwide population-based study

Speaker: Doctor T. Rhee (Seoul, KR)

Association between renal function and clinical outcomes in elderly patients with nonvalvular atrial fibrillation: sub-analysis of the ANAFIE Registry

Speaker: Professor W. Shimizu (Tokyo, JP)

The impact of maternal hypothyroidism on the prevalence of preeclampsia in a contemporary nationwide cohort.

Speaker: Doctor S. Alampoondi Venkataramanan (Worcester, US)

Access the full session

Cardiovascular Disease in Special Populations ePosters

Speakers: Professor D. Cherney, Professor J. McMurray, Doctor C. Su, Doctor T. Rhee, Professor W. Shimizu...

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

Empagliflozin reduces TNFa-induced reactive oxygen species through inhibition of the human endothelial Na+/H+ exchanger 1

27 August 2021

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

This platform is supported by